Pharmaceutical treatments (Varenicline) Source: ERS Course 2015 Year: 2015
Pharmaceutical treatments (Bupropion) Source: ERS Course 2015 Year: 2015
Safety, pharmacodynamics (PD) and pharmacokinetics (PK) of darotropium (DARO) and vilanterol (VI) in healthy subjects: Two phase 1 studies Source: Annual Congress 2013 –Asthma and COPD drugs: efficacy, safety and pharmacoeconomics Year: 2013
Pooled analyses of QTcF across six phase 2b studies with glycopyrrolate-formoterol fumarate (GFF) MDI (PT003), its components and active comparators Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD Year: 2013
Pharmaceutical Treatment Source: Research Seminar 2007 - The limits to exercise in COPD: new insights from new methods Year: 2007
Astro-Lab project: Assessment of the safety of long-acting beta agonists (LABAs) in asthma by combining health-care databases and direct patient follow-up: Description of the patient pattern in France and in the United-Kingdom (UK) Source: Annual Congress 2013 –Treatment and adherence to treatment of respiratory disease Year: 2013
Safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of single (SD) and repeat (RD) inhaled doses of a novel phosphoinositide 3-kinase δ inhibitor (PI3Kδ), GSK2269557, administered to healthy smokers Source: International Congress 2014 – New drugs for asthma, COPD and pulmonary fibrosis Year: 2014
Cost effectiveness of inpatient initiated varenicline tartrate (VT) plus counselling compared to counselling alone: 2 year follow-up of the Smoking Termination Opportunity for inPatients (STOP) study Source: International Congress 2016 – Emerging issues in smoking cessation and tobacco products Year: 2016
Oral corticosteroid prescription patterns for asthma in France, Germany, Italy and the UK Source: Eur Respir J, 55 (6) 1902363; 10.1183/13993003.02363-2019 Year: 2020
Integrated analyses of phase II safety data support the safety of glycopyrrolate-formoterol fumarate (GFF) MDI (PT003) and glycopyrrolate (GP) MDI (PT001) in COPD Source: Annual Congress 2013 –COPD drugs: new findings Year: 2013
Treatment of tobacco addiction using the feeling-state addiction protocol (FSAP) of the eye movement desensitization and reprocessing (EMDR) treatment Source: Annual Congress 2013 –Smoking cessation for healthy and non-healthy smokers Year: 2013
The Innovative Medicines Initiative (IMI), a promising partnership to deliver new medicines to patients Source: Year: 2008
New oral anticoagulants (NOACs) vs. warfarin: Are doctors ready to switch? Source: International Congress 2015 – New developments in medical education, web and internet Year: 2015
Effectiveness of N-acetyl cyctein (NAC) to reduce cough when used together with other over-the-counter (OTC) in common cold (a preliminary study) Source: Annual Congress 2008 - Advances in the treatment and pathogenesis of pulmonary diseases Year: 2008
Effect of severe renal impairment (SRI) on umeclidinium (UMEC) and vilanterol (VI) pharmacokinetics (PK) Source: Annual Congress 2013 –COPD drugs: new findings Year: 2013
Hospitalisation costs for community-acquired pneumonia (CAP) in France (F), Germany (D), Japan (J) and USA Source: Eur Respir J 2004; 24: Suppl. 48, 8s Year: 2004
The impact of antimicrobial resistance on the cost-effectiveness of empirical treatment of community-acquired pneumonia (CAP) in France (FR), Belgium (BE) and Germany (DE) Source: Annual Congress 2007 - Community-acquired pneumonia: from aetiology to complication Year: 2007
Bupropion hydrochloride (Zyban™) is effective and well tolerated as an aid to smoking cessation - a multicountry study Source: Eur Respir J 2001; 18: Suppl. 33, 11s Year: 2001